Extraction Method for Radiomics Feature Information of Knee Joint Effusion

    公开(公告)号:US20220092777A1

    公开(公告)日:2022-03-24

    申请号:US17483747

    申请日:2021-09-23

    Abstract: The disclosure belongs to the technical field of radiomics, and particularly relates to an extraction method for radiomics feature information of knee joint effusion. each layer of an image is segmented into a plurality of regions, the interference of image noises in each region is removed, then whether each region after interference removal is an effusion region or not is judged, finally, the radiomics features of each effusion region are calculated, interpolation processing is respectively implemented on the obtained image position and the area of the effusion regions, an effusion area simulation change curve is drawn, curve integration is implemented to obtain volume information, and all the extracted information is stored in a cell array of a MATLAB. thus the effusion information in the MRI image of the knee joint is automatically extracted, and meanwhile, the method is fast in speed, high in accuracy, good in repeatability.

    1,4-DIPHENYL-1H-IMIDAZOLE AND 2,4-DIPHENYLTHIAZOLE DERIVATIVES AND PREPARATION METHOD THEREFOR AND USE THEREOF

    公开(公告)号:US20210017189A1

    公开(公告)日:2021-01-21

    申请号:US17043646

    申请日:2018-04-09

    Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.

    Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use

    公开(公告)号:US10759757B2

    公开(公告)日:2020-09-01

    申请号:US15271368

    申请日:2016-09-21

    Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

    Short peptide targeting EPS8 binding with EGFR and use thereof

    公开(公告)号:US09828412B2

    公开(公告)日:2017-11-28

    申请号:US14758955

    申请日:2014-12-25

    CPC classification number: C07K7/06 A61K38/00

    Abstract: The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N′-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C′. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs.

    SUPPORT UNIT, SUPPORT DEVICE, AND EMISSION TOMOGRAPHY DEVICE USING SUPPORT DEVICE

    公开(公告)号:US20170303871A1

    公开(公告)日:2017-10-26

    申请号:US15525947

    申请日:2015-11-06

    CPC classification number: A61B6/037 A61B6/42 A61B6/44

    Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device. When the fastening means (240A, 240B) are located at the contraction position, a first detector fastening ring of a first diameter is formed, and when the fastening means (240A, 240B) are located at the extension position, a second detector fastening ring of a second diameter that is smaller than the first diameter is formed. The emission tomography device using the support unit (200) can adjust at least a radial length of a detection chamber, so that a relatively large three-dimensional space angle can be obtained, thereby improving detection sensitivity.

    Use of an urushiol compound in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation
    7.
    发明授权
    Use of an urushiol compound in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation 有权
    在制备用于抑制Smad3磷酸化的药物组合物中使用漆酚化合物

    公开(公告)号:US09139502B2

    公开(公告)日:2015-09-22

    申请号:US14531309

    申请日:2014-11-03

    CPC classification number: C07C39/19 A61K31/05

    Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-β type I receptor (TβRI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as α-smooth muscle actin (α-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-β1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.

    Abstract translation: 本发明涉及一种用于抑制Smad3磷酸化的药物组合物的漆酚化合物(代号GQ-5)的用途。 我们验证GQ-5抑制Smad3与TGF-β的相互作用; I型受体(T&bgr; RI)抑制Smad3的随后的磷酸化,减少Smads复合物的核易位,并抑制主要纤维化基因如α-平滑肌肌动蛋白(α-SMA),胶原I和纤连蛋白的转录。 因此,GQ-5可能是TGF-β1诱导的Smad3磷酸化的有效和选择性抑制剂,可用于制备抑制Smad3磷酸化的药物组合物。

    USE OF AN URUSHIOL COMPOUND IN PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR INHIBITING SMAD3 PHOSPHORYLATION
    8.
    发明申请
    USE OF AN URUSHIOL COMPOUND IN PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR INHIBITING SMAD3 PHOSPHORYLATION 有权
    在制备用于抑制SMAD3磷酸化的药物组合物中的URUSHIOL化合物的使用

    公开(公告)号:US20150175511A1

    公开(公告)日:2015-06-25

    申请号:US14531309

    申请日:2014-11-03

    CPC classification number: C07C39/19 A61K31/05

    Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-β type I receptor (TβRI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as α-smooth muscle actin (α-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-β1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.

    Abstract translation: 本发明涉及一种用于抑制Smad3磷酸化的药物组合物的漆酚化合物(代号GQ-5)的用途。 我们验证GQ-5抑制Smad3与TGF-β的相互作用; I型受体(T&bgr; RI)抑制Smad3的随后的磷酸化,减少Smads复合物的核易位,并抑制主要纤维化基因如α-平滑肌肌动蛋白(α-SMA),胶原I和纤连蛋白的转录。 因此,GQ-5可能是TGF-β1诱导的Smad3磷酸化的有效和选择性抑制剂,可用于制备抑制Smad3磷酸化的药物组合物。

    Support unit, support device, and emission tomography device using support device

    公开(公告)号:US10188357B2

    公开(公告)日:2019-01-29

    申请号:US15525947

    申请日:2015-11-06

    Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device. When the fastening means (240A, 240B) are located at the contraction position, a first detector fastening ring of a first diameter is formed, and when the fastening means (240A, 240B) are located at the extension position, a second detector fastening ring of a second diameter that is smaller than the first diameter is formed. The emission tomography device using the support unit (200) can adjust at least a radial length of a detection chamber, so that a relatively large three-dimensional space angle can be obtained, thereby improving detection sensitivity.

Patent Agency Ranking